Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Neurology

• Publication date

  1998-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1212/WNL.51.1_Suppl_1.S30PMID 9674760
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abnormalities of neural circuitry in Alzheimer's disease

  1998cited by this paper
• Alzheimer's disease

  1998cited by this paper
• Muscarinic receptor subtype selective toxins.

  1997cited by this paper
• Muscarinic acetylcholine receptor subtype, m2: diverse functional implications of differential synaptic localization.

  1997cited by this paper
• Hippocampal synaptic transmission enhanced by low concentrations of nicotine

  1996cited by this paper
• Intrathecal nicotinic agonist-elicited release of excitatory amino acids as measured by in vivo spinal microdialysis in rats.

  1996cited by this paper
• Propofol regulation of calcium entry pathways in cultured A10 and rat aortic smooth muscle cells

  1996cited by this paper
• Release of [3H]‐noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]‐dopamine release

  1996cited by this paper
• p53 Phosphorylation: biochemical and functional consequences.

  1996cited by this paper
• Solution structure of a green mamba toxin that activates muscarinic acetylcholine receptors, as studied by nuclear magnetic resonance and molecular modeling.

  1995cited by this paper
• The body language of cells: the intimate connection between cell adhesion and behavior.

  1995cited by this paper
• Acetylcholinesterase inhibition by fasciculin: crystal structure of the complex.

  1995cited by this paper
• Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors.

  1995cited by this paper
• Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.

  1994cited by this paper
• The cholinesterases: from genes to proteins.

  1994cited by this paper
• Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein

  1991cited by this paper
• Cushing's syndrome in patients with the Zollinger-Ellison syndrome.

  1986cited by this paper
• Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

  1986cited by this paper
• Goodman & Gilman's The Pharmacological Basis of Therapeutics

  1985cited by this paper
• Anticholinesterase Agents.

  1963cited by this paper

• Orthonasal bioactive volatiles and their effects on salivation: a pilot study

  2026cites this paper
• Targeting muscarinic receptors for treating schizophrenia.

  2026cites this paper
• Cell Type-Specific Studies of Human Tissue for Investigation of the Molecular Cell Biology of Late-Onset Neurodegenerative Disease.

  2025cites this paper
• From scent to saliva: The saliva-stimulating effect of terpenes in dry mouth.

  2025cites this paper
• Anticholinesterases Traits Inbuilt in Buxaceae Plant Extracts against Alzheimer’s Disease

  2025cites this paper
• The therapeutic potential of glycyrrhizic acid and its metabolites in neurodegenerative diseases: Evidence from animal models.

  2024cites this paper
• Alkaloids as drug leads in Alzheimer's treatment: Mechanistic and therapeutic insights.

  2024cites this paper
• Fragment Screening in the Development of a Novel Anti-Malarial

  2023cites this paper
• Recent advances in enzyme inhibition based-electrochemical biosensors for pharmaceutical and environmental analysis

  2023cites this paper
• The Human-Restricted Isoform of the α7 nAChR, CHRFAM7A: A Double-Edged Sword in Neurological and Inflammatory Disorders

  2022cites this paper
• Cholinesterase as a Target for Drug Development in Alzheimer's Disease.

  2020cites this paper
• Targeting Enzymes for Pharmaceutical Development: Methods and Protocols

  2020cites this paper
• Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF

  2019cites this paper
• A REVIEW ON RECENT UPDATES OF ACETYLCHOLINESTERASE INHIBITORS FROM PLANT SOURCES

  2018cites this paper
• Identification of Early-Stage Alzheimer's Disease Using Sulcal Morphology and Other Common Neuroimaging Indices

  2017cites this paper
• Reversible Pisa Syndrome Induced by Rivastigmine in a Patient With Early-Onset Alzheimer Disease.

  2017cites this paper
• THE FLUCTUATION ANALYSIS OF CONFORMATIONAL MOBILITY FOR PYRIDOXINE DERIVATIVES IN THE ACTIVE SITE OF ACETYLCHOLINESTERASE

  2016cites this paper
• The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function.

  2015cites this paper
• Patterns of Innovation in Alzheimer's Disease Drug Development: A Strategic Assessment Based on Technological Maturity.

  2015cites this paper
• Cholinesterase Inhibitors and Pisa Syndrome: A Pharmacovigilance Study

  2014cites this paper
• Synthesis and the Inhibitory Effects of Amino Acid Derivatives of β-Boswellic Acid on Acetylcholinestrase

  2014cites this paper
• Molecular Characterization of Monoclonal Antibodies that Inhibit Acetylcholinesterase by Targeting the Peripheral Site and Backdoor Region

  2013cites this paper
• CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease

  2013cites this paper
• In vitro enzyme inhibition activities of Myrtus communis L.

  2012cites this paper
• Докинг производных пиридоксина в активном центре холинэстераз

  2011cites this paper
• Inactivation of acetylcholinesterase by various fluorophores

  2010cites this paper
• Acetylcholinesterase as a Pharmacological Target in Cancer Research

  2010cites this paper
• Inhibition studies of serine hydrolases by cyclic phosphates and phosphonates

  2010influential citation
• Synthesis and AChE inhibitory activity of new chiral tetrahydroacridine analogues from terpenic cyclanones.

  2010cites this paper
• Conformational remodeling of femtomolar inhibitor-acetylcholinesterase complexes in the crystalline state.

  2010cites this paper
• Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinesterase/butyrylcholinesterase.

  2009cites this paper
• In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048

  2009cites this paper
• Cholinesterase Inhibitors from Plants : Possible Treatment Strategy for Neurological Disorders – A Review

  2009cites this paper
• Acetylcholinesterase and apoptosis

  2008cites this paper
• Enzyme inhibition activities of teucrium royleanum

  2007cites this paper
• Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer’s disease

  2007cites this paper
• Enzyme inhibition activities of Teucrium royleanum.

  2007cites this paper
• Inhibition activities of colchicum luteum baker on lipoxygenase and other enzymes

  2006cites this paper
• Metrifonate: A Cholinesterase Inhibitor for Alzheimer's Disease Therapy

  2006cites this paper
• Pesticides and Pesticide Mixtures Induce Neurotoxicity: Potentiation of Apoptosis and Oxidative Stress

  2006cites this paper
• Solvent‐Free Synthesis of Arylamides and Arylimides, Analogues of Acetylcholine

  2005cites this paper
• In vitro inhibitory effect of aflatoxin B1 on acetylcholinesterase activity in mouse brain.

  2005cites this paper
• Ex vivo anticholinesterase activity of benzoic acid derivatives.

  2005cites this paper
• Memantine does not influence AChE inhibition in rat brain by donepezil or rivastigmine but does with DFP and metrifonate in in vivo studies

  2005cites this paper
• Quantitative structure‐activity relationships for the pre‐steady state acetylcholinesterase inhibition by carbamates

  2005cites this paper
• In vitro enzyme inhibition activities of crude ethanolic extracts derived from medicinal plants of Pakistan

  2005cites this paper
• Probing the peripheral anionic site of acetylcholinesterase with quantitative structure activity relationships for inhibition by biphenyl‐4‐acyoxylate‐4′‐N‐Butylcarbamates

  2005cites this paper
• Update on myasthenia gravis

  2004cites this paper
• New cholinesterase inhibiting bisbenzylisoquinoline alkaloids from Cocculus pendulus.

  2004cites this paper
• A 12-Month Study of the Efficacy of Rivastigmine in Patients with Advanced Moderate Alzheimer’s Disease

  2004cites this paper
• N-methylpiperidinemethyl, N-methylpyrrolidyl and N-methylpyrrolidinemethyl esters as PET radiotracers for acetylcholinesterase activity.

  2003cites this paper
• The Cholinesterase Inhibitors

  2003cites this paper
• In vitro Inhibition of Acetylcholinesterase, Butyrylxcholinesterase and Lipoxygenase by Crude Extract of Myricaria elegans Royle

  2003cites this paper
• Reversible and irreversible inhibitory activity of succinic and maleic acid derivatives on acetylcholinesterase.

  2003cites this paper
• 5-Hydroxytryptamine 1A Receptor Activation Protects againstN-Methyl-d-aspartate-Induced Apoptotic Cell Death in Striatal and Mesencephalic Cultures

  2003cites this paper
• Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5‐I‐A‐85380

  2003cites this paper
• Inhibition of acetylcholinesterase by physostigmine analogs: Conformational mobility of cysteine loop due to the steric effect of the alkyl chain

  2002cites this paper
• Intravenous immunoglobulin in neurological disease: a specialist review

  2002cites this paper
• Barriers to drug discovery and development for Alzheimer disease.

  2002influential citation
• Induction of acetylcholinesterase expression during apoptosis in various cell types

  2002cites this paper
• Biotransformation of alkaloids.

  2002cites this paper
• [Treatment of Alzheimer's disease].

  2002cites this paper
• New cholinesterase inhibiting steroidal alkaloids from the leaves of Sarcococca coriacea of Nepalese origin.

  2002cites this paper
• Pharmacologic treatments of dementia.

  2002cites this paper
• Review of drug development and therapeutic role of cholinesterase inhibitors in Alzheimer's disease

  2002cites this paper
• Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.

  2001cites this paper
• Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane

  2001cites this paper
• Radiolabeled Cholinesterase Substrates: In Vitro Methods for Determining Structure-Activity Relationships and Identification of a Positron Emission Tomography Radiopharmaceutical for In Vivo Measurement of Butyrylcholinesterase Activity

  2001influential citation
• Cholinergic Lesions as a Model of Alzheimer’s Disease

  2000cites this paper
• Inhibition of Ache: Structure-Activity Relationship Among Conformational Transition of Trp84 and Bimolecular Rate Constant

  2000cites this paper
• Treatment of Alzheimer's disease.

  2000cites this paper
• The effects of physostigmine and cholinergic receptor ligands on novelty-induced neophobia

  2000cites this paper
• Cholinesterase inhibitors: A new class of psychotropic compounds.

  2000cites this paper
• Treatment of Alzheimer's disease.

  2000cites this paper
• Evidence for Psychotropic Effects of Acetylcholinesterase Inhibitors

  2000cites this paper
• Inactivation studies of acetylcholinesterase with phenylmethylsulfonyl fluoride.

  2000cites this paper
• Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors.

  2000cites this paper
• AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys

  2000cites this paper
• Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy

  2000influential citation
• Neurotransmitterveränderungen bei der Alzheimer Demenz

  1999cites this paper